A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

Clinical trial NCT06961006 · RECRUITING

Trial details

NCT number: NCT06961006
Sponsor: Merck Sharp & Dohme LLC
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Malignant Melanoma

Start date: 2025-05-29
Primary completion: 2028-07-22
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.